# Genetic Diversity and Levels of Expression of Factor H Binding Protein among Carriage Isolates of Neisseria meningitidis.

Ludovic Lemée, Eva Hong, Manuel Etienne, Ala-Eddine Deghmane, Valérie Delbos, Aude Terrade, Gilles Berthelot, François Caron, Muhamed-Kheir Taha

<figure><img src="image_1.png" /></figure>

## To cite this version:

Ludovic Lemée, Eva Hong, Manuel Etienne, Ala-Eddine Deghmane, Valérie Delbos, et al.. Genetic Diversity and Levels of Expression of Factor H Binding Protein among Carriage Isolates of Neisseria meningitidis.. PLoS ONE, 2014, 9 (9), pp.e107240. 10.1371/journal.pone.0107240. pasteur-02072510

HAL Id: pasteur-02072510

https://pasteur.hal.science/pasteur-02072510

Submitted on 19 Mar 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

<figure><img src="image_2.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
# Genetic Diversity and Levels of Expression of Factor H Binding Protein among Carriage Isolates of *Neisseria meningitidis*

Ludovic Lemée¹,⁹, Eva Hong²,⁹, Manuel Etienne¹, Ala-Eddine Deghmane², Valérie Delbos¹, Aude Terrade², Gilles Berthelot³, Francois Caron¹,⁴, Muhamed-Kheir Taha²*

¹Centre Hospitalier Universitaire, Rouen, France, ²Institut Pasteur, National de Reference Centre for meningococci and Invasive Bacterial infections Unit, Paris, France,

³Centre Hospitalier Général, Dieppe, France

## Abstract

The prevention of meningococcal disease may be improved by recombinant vaccines such as 4CMenB and rLP2086 that target the factor H binding protein (fHbp), an immunogenic surface component of *Neisseria meningitidis* present as one of three variants. Whether such vaccines decrease carriage of invasive isolates and thus induce herd immunity is unknown. We analyzed the genetic diversity and levels of expression of fHbp among 268 carriage strains and compare them to those of 467 invasive strains. *fhbp* gene sequencing showed higher proportions of variants 2 and 3 among carriage isolates (p< 0.0001). Carriage isolates expressed lower levels of fHbp (p<0.01) but that remain high enough to predict targeting by antibodies against fHbp particularly in group B isolates belonging to the frequent hypervirulent clonal complexes in Europe and North America (cc32, cc41/44, cc269). This suggests that fHbp targeting meningococcal vaccines might reduce, at least in part, the acquisition of some hyperinvasive isolates.

**Citation:** Lemée L, Hong E, Etienne M, Deghmane A-E, Delbos V, et al. (2014) Genetic Diversity and Levels of Expression of Factor H Binding Protein among Carriage Isolates of *Neisseria meningitidis*. PLoS ONE 9(9): e107240. doi:10.1371/journal.pone.0107240

**Editor:** Brian Stevenson, University of Kentucky College of Medicine, United States of America

**Received** July 25, 2014; **Accepted** August 7, 2014; **Published** September 23, 2014

**Copyright:** © 2014 Lemée et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability:** The authors confirm that all data underlying the findings are fully available without restriction. All fHbp alleles are indicated in the Supplementary Table and full sequences are available on PubMLST database (http://pubmlst.org/neisseria/) through the dropmenu (fHbp_PEPTIDEfrag_Pasteur and fHbp_DNAfrag_Pasteur)

**Funding:** The study was supported by institutional funding by the French Ministry of Health "Programme Hospitalier de Recherche Clinique," the Institut Pasteur, and the Institut de Veille. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

## Introduction

Invasive meningococcal diseases (IMD) such as meningitis and meningococcemia remain in all countries one of the leading cause of death from bacterial infection in otherwise healthy young subjects [1]. While meningococcal carriage in the nasopharynx is common (estimated to concern about 10% of the general population [2]), invasion is a rare phenomenon, excepted during outbreaks. Numerous studies have shown that disease isolates (i.e. isolates from IMD cases) differ from carriage isolates, belonging to a limited number of genetic lineages or clonal complexes (cc) known for their virulence [3]. For example, in Europe and North America, five clonal complexes (cc8, cc11, cc32, cc41/44 and cc269) are responsible for most IMD cases [3,4]. Usually, IMD occurs upon a recent acquisition of such pathogenic isolates that escape innate host immunity (complement mediated bacterial lysis and phagocytosis) due to meningococcal virulence factors such as the capsule and the ability to bind negative regulators of complement pathway [5].

Most IMD in Europe, America and Oceania are due to group B isolates [6]. Their prevention might be revolutionized at short term by a recently licensed recombinant vaccine containing 4

components (4CMenB/Bexsero) that is expected to offer a broad group B isolates coverage [7]. Another bivalent recombinant vaccine (rLP2086) is also under development [8]. Both of these vaccines target the factor H binding protein (fHbp), an immunogenic surface component known to contribute to the virulence of *Neisseria meningitidis* through binding of the negative regulator of the alternative pathway of the complement [5]. Because fHbp also exists in non group B meningococcal isolates, a coverage of some of these isolates is expected, as recently shown for 4CMenB/ Bexsero against some group X isolates (from Africa but not from Europe) [9].

One key-question for these fHbp-based vaccines concerns their ability to decrease meningococcal acquisition/carriage of invasive isolates and thus to induce herd immunity, as previously shown for conjugate meningococcal C vaccine.

Carriage studies currently performed among subjects receiving 4CMenB/Bexsero or rLP2086 (clinicalTrials.gov identifier NCT01214850) will probably help answering the question, providing they will not be biased by a local ecology that do not necessary reflect the global epidemiology. An alternative approach to anticipate the potential herd immunity effect of recombinant meningococcal vaccines can be achieved by analyzing the genetic

<footnote>* Email: mktaha@pasteur.fr</footnote>

<footnote>¶ These authors contributed equally to this work.</footnote>

<footnote>‡ FC and M-KT contributed similarly as senior investigators on this work.</footnote>
<table><caption>**Table 1.** Overall phenotypic and genotypic diversity of *N. meningitis* isolates from France in 2008, either from healthy carriers (i.e., carriage isolates) or from cases of invasive meningococcal disease (i.e., invasive isolates).</caption><thead><tr><th></th><th>Carriage isolates</th><th>Disease isolates</th><th>p</th></tr></thead><tbody><tr><td>Serogrouping:</td><td>n = 188</td><td>n = 487</td><td></td></tr><tr><td>non serogroupeable isolates</td><td>92 (48.9%)</td><td>3 (0.6%)</td><td>&lt;0.007*</td></tr><tr><td>serogroupeable isolates</td><td>96 (51.1%)</td><td>484 (99.4%)</td><td>&lt;0.007*</td></tr><tr><td>serogroup B</td><td>46 (24.5%)</td><td>318 (65.3%)</td><td>&lt;0.007*</td></tr><tr><td>serogroup C</td><td>16 (8.5%)</td><td>115 (23.6%)</td><td>&lt;0.007</td></tr><tr><td>serogroup Y</td><td>16 (8.5%)</td><td>30 (6.2%)</td><td>ns</td></tr><tr><td>serogroup W</td><td>6 (3.2%)</td><td>21 (4.3%)</td><td>ns</td></tr><tr><td>serogroup X</td><td>4 (2.1%)</td><td>0 (0%)</td><td>&lt;0.007*</td></tr><tr><td>others</td><td>8 (4.3%)</td><td>0 (0%)</td><td>&lt;0.007*</td></tr><tr><td>Genogrouping:</td><td>n = 188</td><td>n = 487</td><td></td></tr><tr><td>non genogroupeable isolates</td><td>69 (36.7%)</td><td>0 (0%)</td><td>&lt;0.008#</td></tr><tr><td>genogroupeable isolates</td><td>119 (63.3%)</td><td>487 (100%)</td><td>&lt;0.008#</td></tr><tr><td>genogroup B</td><td>67 (35.6%)</td><td>319 (65.5%)</td><td>&lt;0.008#</td></tr><tr><td>genogroup C</td><td>24 (12.8%)</td><td>116 (23.8%)</td><td>&lt;0.008#</td></tr><tr><td>genogroup Y</td><td>16 (8.5%)</td><td>31 (6.3%)</td><td>ns</td></tr><tr><td>genogroup W</td><td>7 (3.7%)</td><td>21 (4.3%)</td><td>ns</td></tr><tr><td>genogroup X</td><td>5 (2.7%)</td><td>0</td><td>&lt;0.008#</td></tr><tr><td>Serosubtyping:</td><td>n = 188</td><td>n = 487</td><td></td></tr><tr><td>non serosubtypeable isolate</td><td>24 (12.8%)</td><td>99 (20.3%)</td><td>ns</td></tr><tr><td>serosubtypeable isolate</td><td>164 (87.2%)</td><td>388 (79.7%)</td><td>ns</td></tr><tr><td>number of serosubtypes</td><td>19</td><td>20</td><td></td></tr><tr><td>Clonal complexes (cc):</td><td>166</td><td>126</td><td></td></tr><tr><td>5 hyperinvasives European clonal cc</td><td>56 (33.7%)</td><td>98 (77.8%)</td><td>&lt;0.008#</td></tr><tr><td>cc8</td><td>0</td><td>0</td><td></td></tr><tr><td>cc 11</td><td>13 (7.8%)</td><td>35 (27.8%)</td><td>&lt;0.008#</td></tr><tr><td>cc 32</td><td>19 (11.4%)</td><td>13 (10.3%)</td><td>ns</td></tr><tr><td>cc 41/44</td><td>21 (12.7%)</td><td>40 (31.7%)</td><td>&lt;0.008#</td></tr><tr><td>cc 269</td><td>3 (1.8%)</td><td>10 (7.9%)</td><td>ns</td></tr><tr><td>Genetic diversity. Simpson's Index</td><td>0.974</td><td>0.901</td><td>0.002</td></tr><tr><td>95% Confidence Interval</td><td>0.963-0.942</td><td>0.859-0.942</td><td></td></tr><tr><td>Antibiotic susceptibility testing; susceptibility to:</td><td>n = 188</td><td>n = 487</td><td></td></tr><tr><td>penicillin G</td><td>124 (66%)</td><td>380 (78%)</td><td>0.007</td></tr><tr><td>cefotaxime/ceftriaxone</td><td>188</td><td>487</td><td></td></tr><tr><td>rifampicin</td><td>188</td><td>487</td><td></td></tr><tr><td>ciprofloxacin</td><td>188</td><td>487</td><td></td></tr></tbody></table>

*Bonferroni correction for 7 comparisons.

\#Bonferroni correction for 6 comparisons.

ns: non significant.

doi:10.1371/journal.pone.0107240.t001

diversity and levels of expression of fHbp among current carriage isolates. Indeed, the protective effect against carriage of meningococcal recombinant vaccines is supposed to be dependent on the cross-reactivity with the vaccine fHbp and the level of expression of fHbp in virulent isolates in sitting of carriage, the higher the expression, the higher the protection is.

Thus, the aim of this study was to analyze the fHbp expression among carriage meningococcal isolates currently encountered in France, and to compare them to those observed among disease isolates.

## Methods

### Bacterial isolates and ethical statement

**Collection of carriage isolates.** Carriage isolates came from a study conducted in the early 2008 during a clonal B:14:P1.7,16/ ST-32 meningococcal outbreak that had affected a part of the French Normandy region from 2003 to 2010 [10]. This carriage study has been previously detailed [11]. It was approved by the Regional Ethical Committee for Medical Research (Comité de Protection des Personnes Nord-Ouest, CPP NordOuest) as well as the National French Data Protection Agency (Commission Nationale Informatique et Liberté). Written informed consent
<figure><img src="image_3.png" /></figure>

<figure><img src="image_4.png" /></figure>
**Figure 1. Phylogenetic relationships between carriage and invasive isolates.** On the right side of the figure the carriage isolates are displayed (n=124). The invasive isolates for which full MLST data were available (n=126) are on the left side of the figure. Relationships and clustering of typing data were performed using the START package available through (http://pubmlst.org). doi:10.1371/journal.pone.0107240.g001

was obtained from parents or legal guardian of each participant. Out of 3522 volunteers aged 1–25 years, 196 had a detectable pharyngeal carriage of *N. meningitidis* (all isolates included), with only one isolate detected by subject (i.e., no detection of polyclonal carriage). Among these 196 subjects, 112 had a second swab, in a mean delay of 6.7 days after the first (range, 4–12 days); most of them (87/112, 78%) still carried a *N. meningitidis* isolate, which was identical or closely related to the isolate of the first swab for almost all subjects (see details below).

Because some isolates were not recovered after subculture, the final collection of carriage isolates included a total of 268 isolates that corresponded to 188 subjects. For these subjects, 101 had only primary-swab isolates, 80 had both primary and secondary swabs isolates, and 7 subjects had only secondary swab isolates. Given the extremely low level of carriage of the epidemic B:14:P1.7,16/ST-32 strain (see below), this collection was supposed to well reflect the isolates responsible for healthy meningococcal carriage at the country level [11].

**Collection of disease isolates.** Disease isolates came from the collection of the National Reference Centre for Meningococci (NRCM) at the Pasteur Institute. For that collection the NRCM had approvals from the internal board of the Institut Pasteur to collect, characterize and use these samples that are all anonyzed, and that of the National French Data Protection Agency (Commission Nationale Informatique et Liberté). To avoid the overrepresentation of B:14:P1.7,16/ST-32 observed in Normandy (which represented up to 80% of the total disease isolates at the acme of the outbreak) all the 487 culture-confirmed disease isolates collected in France in 2008 were analyzed. Such collection reflects well the isolates responsible for IMD at the country level. Indeed, in France, for each case of IMD, it is requested that the isolate at a local level is send to the NRCM for complete typing.

## Phenotypic and genotypic characterization of meningococcal isolates

All the carriage and disease isolates were typed at the NRCM in

cooperation with the Rouen University hospital. They were grown under 5% CO₂ on GCB agar plate with Kellogg supplements [12], and characterized by phenotyping (serogroup:serotype:serosub-type), antibiotic susceptibility testing and genotyping by both capsule gene amplification, multilocus sequence typing (MLST), pulse-filed gel electrophoresis (with two restriction enzymes, NheI and SpeI) and porA typing [13,14,15]. Antibiotic susceptibility testing to define the minimal inhibitory concentrations for penicillin G, cefotaxime, ceftriaxone, ciprofloxacin and rifampicin was performed using Etest (BioMérieux, Marcy l'Etoile, France) on Mueller-Hinton agar plates supplemented with sheep blood and interpreted as previously described [15]. Full MLST data (sequence types and clonal complexes) were obtained for 126 disease isolates (each fourth isolate representing 25% of the total 487 isolates). For the carriage isolates full MLST data were obtained for 166 isolates.

## fHbp analysis

For the total set of carriage isolates (268 isolates), the genetic diversity and levels of expression of meningococcal factor H binding protein were analyzed, using methods previously described [16]. The sequence of *fHbp* gene was performed to determine the distribution of the corresponding allele using primers and sequencing methods that we have previously reported [16].

The level of the expression of *fHbp* was quantified by ELISA and using anti-*fHbp* antibodies directed against both subfamilies (*fHbp* variant 1/family B and variant 2 or 3/family A). These antibodies were obtained in rabbits that were immunized with purified *fHbp*. After immunization, antibodies were purified from rabbit sera, and then used in ELISA tests as previously described [16]. The results obtained with the carriage isolates were compared to those previously observed for the disease isolates which have been published elsewhere [16].

Susceptibility to anti-*fHbp* antibodies of the selected strains was also analysed. Titration of bactericidal activity was performed

<table><caption>**Table 2.** Distribution of groups and clonal complexes (numbers and percentages) of carriage isolates according to their levels of production of *fHbp*.</caption><thead><tr><th rowspan="2"></th><th colspan="2">fHbp-negative isolates (n = 60, 32%)</th><th colspan="2">fHbp-producing isolates n = 128, 68%)</th><th rowspan="2">p</th></tr><tr><th>Serogroup</th><th>Genogroup</th><th>Serogroup</th><th>Genogroup</th></tr></thead><tbody><tr><td>B</td><td>15 (25%)</td><td>19 (31.7%)</td><td>31 (24.2%)</td><td>47 (36.7%)</td><td>ns</td></tr><tr><td>C</td><td>13 (21.7%)</td><td>14 (23.3%)</td><td>3 (2.3%)</td><td>10 (7.8%)</td><td>≤0.01#</td></tr><tr><td>Y</td><td>11 (18.3%)</td><td>12 (20%)</td><td>5 (3.9%)</td><td>4 (3.1%)</td><td>≤0.01#</td></tr><tr><td>W</td><td>0 (0%)</td><td>0 (0%)</td><td>6 (4.7%)</td><td>7 (5.5%)</td><td>ns</td></tr><tr><td>NG and others</td><td>21 (35%)</td><td>15 (25%)</td><td>83 (64.9%)</td><td>60 (46.9%)</td><td>≤0.01#</td></tr><tr><td>All hyperinvasive cc</td><td>16 (26.7%)</td><td></td><td>40 (31.2%)</td><td></td><td>ns</td></tr><tr><td>cc32, cc41/44, cc269</td><td>5 (8.3%)</td><td></td><td>38 (29.7%)</td><td></td><td>0.0125*</td></tr><tr><td>cc11</td><td>11 (18.3%)</td><td></td><td>2 (1.7%)</td><td></td><td>0.0125*</td></tr><tr><td>other cc</td><td>44 (73.3%)</td><td></td><td>88 (68.8%)</td><td></td><td>ns</td></tr></tbody></table>

# Bonferroni correction for 5 comparisons.

*Bonferroni correction for 4 comparisons.

ns: non significant.

doi:10.1371/journal.pone.0107240.t002
<table><caption>**Table 3.** Values of ratios of fHbp expression level among carriage and invasive isolates.</caption><thead><tr><th rowspan="2">Clonal complexes</th><th colspan="2">Mean fHbp expression ratio (IC 95%)</th><th rowspan="2">p</th></tr><tr><th>Carriage isolates (n = 188)</th><th>Disease isolates (n = 102)</th></tr></thead><tbody><tr><td>cc11</td><td>0.014 (-0.007-0.036)</td><td>0.73 (0.49-0.97)</td><td>0.0002</td></tr><tr><td>cc32</td><td>1.7 (1.1-2.2)</td><td>2.6 (1.8-3.5)</td><td>0.0182</td></tr><tr><td>cc41/44</td><td>0.39 (0.23-0.54)</td><td>0.97 (0.78-1.2)</td><td>0.0001</td></tr><tr><td>cc269</td><td>0.97 (-1.3-3.3)</td><td>1.3 (0.62-2)</td><td>0.7143</td></tr><tr><td>Others</td><td>0.3 (0.23-0.37)</td><td>0.37 (0.18-0.57)</td><td>0.9875</td></tr><tr><td>All</td><td>0.43 (0.34-0.53)</td><td>0.92 (0.74-1.1)</td><td>&lt;0.0001</td></tr></tbody></table>

p value ≤0.008 for significance (Bonferroni correction for 6 comparisons).

doi:10.1371/journal.pone.0107240.t003

using the previously described anti-fHbp IgG that are directed against variants 1, 2 and 3 of fHbp [16]. Assays were performed with several carriage isolates and a human serum as an exogenous complement source as previously described [10]. The titers corresponded to the reciprocal of the final serum dilution causing 50% killing of the inoculum. Bactericidal titers lower than 4 were assigned a value of 2.

## Data analysis

Isolates for which the expression of an A, B, C, Y, W, X, or E capsule was detected by agglutination were designated as “serogroupeable isolates”. Isolates were also tested by PCR for the specific genes serogroups A, B, C, Y, W, or X; isolates for which the PCR was positive were designated as “genogroupeable isolates”.

The identification of sequence type (ST) and clonal complexes was performed through (http://pubmlst.org/neisseria/). Relationships and clustering of typing data were performed using the START package available through (http://pubmlst.org) [17]. Alleles of *fHbp* were described according to their classification into two subfamilies or three variants [18]. The expression of fHbp was analysed using the optic densities (OD) obtained by ELISA after subtraction of the background OD (a negative isolate for fHbp).

<figure><img src="image_5.png" /><figcaption>**Figure 2.** Schematic representation of the levels of expression of fHbp overtime among carriage isolates. Data were obtained from 80 subjects for whom two positive pharyngeal swabs were available at a mean of 1 weak interval. For each subject, the data were expressed as ratio of the expression of fHbp from the fist sample and the reference isolate and linked by a solid line to the ratio of the expression of fHbp from the second sample and the reference isolate. doi:10.1371/journal.pone.0107240.g002</figcaption></figure>

The results were expressed as a ratio over that of the positive control and were analyzed using Z Score transformation as previously described [16]. OD data were log transformed and normalized to the mean of log ratios of all ODs measures and then expressed as unit of standard deviation (SD) above/below the mean of log ratios, a Z score ≤-2 corresponding to low expression of fHbp.

For the comparison between carriage isolates and diseases isolates, only one isolate by patient was retained (i.e., the doubloons of the carriage isolates set were excluded to avoid an overrepresentation at the corresponding isolates).

Data were analyzed using the Chi-squared test, Student's t-test and analysis of variance (ANOVA). A P value of ≤0.05 was considered to be statistically significant. When Chi-squared test involved several comparisons, the Bonferroni correction was applied.

## Results

### 1- Overall phenotypic and genotypic diversity of carriage isolates compared to disease isolates

Higher diversities of phenotypes and genotypes were observed for the carriage isolates, compared to disease isolates, as summarized in Table 1.

While all invasive isolates were capsulated, i.e., were serogroupeable, only half of the carriage isolates (96/188, 51.1%) showed a serogroupable phenotype. However, among the 92 non serogroupeable carriage isolates, 35 (18.6% of the total set) were genogroupeable, suggesting that such isolates could be potentially virulent, should they be able to recover the expression of capsule genes. Among the remainder 57 non genogroupeable carriage isolates, 41 (21.8% of the total set) were positive for null capsule locus (cnl), suggesting a total absence of virulence. The carriage isolates also showed significantly higher diversity in terms of combinations serotypes/serosubtypes (Table 1). Among the 166 carriage isolates for which a sequence type was determined, 84 sequence types were identified that belonged to 22 different clonal complexes. Only 33.7% of these isolates belonged to one of the five hyperinvasive clonal complexes commonly encountered in Europe (cc8, cc11, cc32, cc41/44 and cc 269). At the opposite, 77.8% of the disease isolates belonged to these 5 hyperinvasive clonal complexes (p<0.008). As a result the overall genetic diversity was significantly higher for carriage isolates than for disease isolates (Simpson's index of diversity 0.974 and 0.901, respectively, p = 0.002), as shown in Fig. 1.

All the carriage and disease isolates were susceptible to ciprofloxacin, rifampicin and cefotaxim. The proportion of isolates
<table><caption>Table 4. Characteristics of carriage isolates and their susceptibility to anti-fHbp rabbit IgG.</caption><thead><tr><th>Isolate</th><th>Group</th><th>Clonal complex</th><th>fHbp peptide</th><th>fHbp DNA</th><th>fHbp variant</th><th>Z score</th><th>survival titre</th></tr></thead><tbody><tr><td>2995</td><td>B</td><td>cc213</td><td>13</td><td>18</td><td>3</td><td>ND</td><td>2</td></tr><tr><td>2934</td><td>B</td><td>cc213</td><td>13</td><td>18</td><td>3</td><td>ND</td><td>2</td></tr><tr><td>2371</td><td>B</td><td>cc213</td><td>13</td><td>18</td><td>3</td><td>ND</td><td>2</td></tr><tr><td>2716</td><td>B</td><td>cc35</td><td>9</td><td>11</td><td>2</td><td>ND</td><td>2</td></tr><tr><td>1046</td><td>C</td><td>cc254</td><td>12</td><td>3</td><td>1</td><td>ND</td><td>2</td></tr><tr><td>1231</td><td>B</td><td>cc213</td><td>13</td><td>18</td><td>3</td><td>ND</td><td>2</td></tr><tr><td>2794</td><td>C</td><td>cc11</td><td>12</td><td>3</td><td>1</td><td>ND</td><td>2</td></tr><tr><td>3601</td><td>B</td><td>cc162</td><td>10</td><td>16</td><td>2</td><td>-4.42</td><td>2</td></tr><tr><td>341</td><td>B</td><td>cc41/44</td><td>1</td><td>24</td><td>2</td><td>-2.21</td><td>2</td></tr><tr><td>3180</td><td>B</td><td>cc32</td><td>3</td><td>31</td><td>1</td><td>1.87</td><td>16</td></tr></tbody></table>

ND: non detectable.
doi:10.1371/journal.pone.0107240.t0004

with reduced susceptibility to penicillin G (MIC ≥0.125 mg/L) was significantly higher for the carriage isolates than for the disease isolates (34% versus 22%, p = 0.007).

## 2- fHbp analysis

Data of *fHbp* gene sequencing were obtained for 187 out of the 188 carriage isolates; they showed 28 different DNA alleles of *fHbp* that encodes 20 different peptides. All *fHbp* alleles are indicated in the Table S1 and full sequences are available on PubMLST database (http://pubmlst.org/neisseria/) through the dropmenu (*fHbp_PEPTIDEfrag_Pasteur* and *fHbp_DNAfrag_Pasteur*). Based on protein sequence data, 51 (27.3%) isolates corresponded to variant 1 of *fHbp*, 93 (49.7%) corresponded to variant 2 of *fHbp* and 43 (23%) belonged to variant 3. The proportion of variant 1 *fHbp* among invasive isolates (regardless the serogroup) was 58%, a proportion significantly higher (p<0.0001) from that observed among carriage isolates. The most frequent *fHbp* allele among carriage isolates was *fHbp11* that encoded peptide9/variant 2. The peptide *fHbp9* accounted for 15.5% (n=29) of peptides of the carriage isolates, while it was of lower frequency among invasive isolates (5.9%). This allele encodes a *fHbp* harbouring the residues that are involved in binding to human factor H [19].

The expression levels of *fHbp* at the bacterial surface were analyzed in all the 188 carriage isolates. Fifty seven isolates (30.3%) did not show any detectable *fHbp*. The remaining 131 isolates were classified according to their distribution around the mean value of *fHbp* ratios (detailed scores are displayed in the Table S1). Three isolates showed Z scores that were ≤−2 standard deviations below the mean. Thus 60 (32%) carriage isolates were considered as *fHbp* negative isolates (57 with no detection and 3 with low score). The group distributions (serogroups and genogroups) of the carriage isolates according to status of expression of *fHbp* is showed in the Table 2. Group C isolates were significantly more present among *fHbp*-negative isolates, and this seems impacted by the role of the clonal complex ST-11; indeed, among the 13 group C carriage isolates belonging to the clonal complex ST-11, only two were *fHbp* positive (Z score >−2).

As shown in Table 3 and Figure 2, the global levels of *fHbp* expression were significantly lower in carriage isolates than in disease isolates. This was also true when the isolates were considered according to their clonal complexes. Indeed, carriage isolates belonging to clonal complex cc11 or cc41/44 showed significant lower levels of *fHbp* compared to the invasive isolates belonging to the respective same clonal complex. In contrast, the differences in terms of *fHbp* expression between carriage and disease isolates was not statistically significant for isolates of the clonal complex cc269 (with the limit of low numbers), for isolates belonging to the cc32 or for isolates that did not belong to any known clonal complexes.

Table 4 shows the susceptibility to rabbit anti-*fHbp* antibodies of 10 carriage isolates expressing *fHbp* at different levels. No killing was observed for the isolates with low or no *fHbp*. In contrast, a carriage isolate that expressed *fHbp* at high level was susceptible to the *fHbp* antibodies, with high bactericidal titers (i.e., 16).

## 3- Variation of carriage at one week interval

Among 80 subjects for which two positive pharyngeal swabs were available (at a mean of 6.7 days interval), 48 (60%) had a second isolate strictly identical to the first one, and 30 (37.5%) had a second isolate that differed but slightly by either their sequence type (but within the same cc), group, serotype or serosubtype. For
<figure><img src="image_6.png" /><figcaption>**Figure 3.** Distribution of relative levels of expression of fHbp among carriage and invasive isolates. Data were expressed as ratios of the expression for each strain compared to a reference strain a scatter plots (filled gray circles) and mean values (black lines). The clonal complexes (cc) to which belong the tested isolates are indicted under each group of scatter plots.
doi:10.1371/journal.pone.0107240.g003</figcaption></figure>

only two subjects (2.5%), the second isolate was clearly different from the first one, both by its group and clonal complex. The expression levels of fHbp at the bacterial surface were available for the pairs of isolates of the 80 subjects. Overall, there was no significant difference (Fig. 3). A marked decrease in fHbp levels was observed for the second isolate in only two cases: a 4 time lower level for a pair of isolates that were genetically related (same cc162) and a 32 times lower level for one of the two subjects for which the second isolate was different.

Interestingly, one subject was carrier of the epidemic strain which was replaced at the second sampling by a non-groupeable isolate of the cc1136 (ST-7454) that also expressed a different fHbp allele.

Discussion

We reported here the first study that had analyzed the levels of surface expression of fHbp among *N. meningitidis* isolates from healthy carriers, and compared them to those observed among invasive isolates collected in the same period on a same country. This fHbp expression is expected to be critical for the bacterial coverage of the new recombinant meningococcal vaccines, which are supposed to act not only by decreasing the risk of IMD at the individual level among immunized subjects, but also by avoiding the decreasing acquisition/transmission of virulent strains and thus to induce herd immunity [20].

In accordance with previous studies [2,21], the carriage isolates here studied displayed higher heterogeneity than invasive isolates for almost all the investigated parameters including group, sequence type, and antibiotic susceptibility profile. In particular, there was a lower proportion of isolates belonging to the hyperinvasive clonal lineages, as shown by the comparison of the respective dendogram and diversity coefficient of each set (Fig. 1).

Carriage isolates were also very heterogenic for fHbp in terms of both DNA sequences and level of expression. While a majority (60%) of invasive isolates harbored fHbp variant 1, carriage isolates were most harmoniously distributed between the three variants; such results are in accordance with a previous work having suggest higher proportion of variants 2 and 3 among invasive *N. meningitides* strains [22]. Also, high sequence diversity

of fHbp was observed among carriage isolates with 28 unique *fHbp* alleles corresponding to 20 unique fHbp proteins.

The most original data of that study concerned the levels of fHbp expression which were globally lower among carriage isolates than invasives isolates. For that analysis we used a tool previously described by the NRCM [16], i.e., rabbit anti fHbp antibodies that allowed ELISA quantification of fHbp at the surface of meningococcal isolates and to correlate these levels to the bactericidal effect of anti-fHbp antibodies. The proportion of isolates with no or low levels of fHbp did not differ significantly among carriage and invasive isolates (32% versus 24% p = 0.13). Such an absence of detectable fHbp seems to prevent the clearance of bacteria by anti-fHbp antibodies (Table 4). Of note, for isolates that expressed fHbp, the level of such expression was globally lower for carriage isolates, but remaining high enough for most hyperinvasive clonal complexes of serogroup B isolates (cc32, cc41/44 and cc269) to expect targeting by antibodies directed against fHbp [16]. This suggests that fHbp based vaccines such as 4CMenB/Bexsero or the bivalent rLP2086 vaccine might decrease nasopharyngeal acquisition and carriage of numerous invasive isolates, and thus induce herd immunity. In addition, fHbp was expressed among carriage isolates regardless the serogroup, confirming that « B recombinant vaccines » would be in fact « universal meningococcal vaccines » [23].

Our results clearly indicate that the levels of expression of fHbp could vary significantly. The importance of this observation may be related to the recent description of thermoregulation that has been suggested to increase the expression of fHbp by the meningococcus when temperature in the nasopharynx increased upon flu infection and hence triggers invasiveness [24]. Carriage isolates, at the opposite of invasive isolates, may not undergo this thermoregulation and retain lower fHbp levels.

In our opinion, evaluating the levels of vaccine-targeted antigens is crucial for studies that aim to address the impact of the new recombinant vaccines on carriage isolates. For the record, the impact of the meningococcal serogroup C conjugate vaccines was observed to be mainly on isolates belonging to the ST-11 clonal complex serogroup C and was suggested to be due to high levels of capsule expression in these carriage isolates [20]. For recombinant meningococcal vaccines targeting fHbp, rabbit anti fHbp antibodies seem useful tools to anticipate the strain coverage
in particular for vaccines containing solely fHbp (LP2086). For 4CMenB/Bexsero, the meningococcal antigen typing system (MATS) approach can be used [25].

Vaccine-induced herd immunity is an essential aspect in controlling meningococcal disease [26]. Our work based on the comparison of carriage isolates and disease isolates suggested that fHbp targeting meningococcal vaccines might reduce, at least in part, the carriage of some hyperinvasive isolates, and thus contribute to establish a herd effect.

## Supporting Information

**Table S1 Characteristics of carriage isolates of N. meningitidis.** Phenotypic and genotypic typing data are

### References

1. Stephens DS, Greenwood B, Brandtzaeg P (2007) Epidemic meningitis, meningococcaemia, and *Neisseria meningitidis*. Lancet 369: 2196-2210.

2. Yazdankhah SP, Kriz P, Tzanakaki G, Kremastinou J, Kalmusova J, et al. (2004) Distribution of Serogroups and Genotypes among Disease-Associated and Carried Isolates of *Neisseria meningitidis* from the Czech Republic, Greece, and Norway. J Clin Microbiol 42: 5146-5153.

3. Zarantonelli ML, Lancellotti M, Deghmane AE, Giorgini D, Hong E, et al. (2008) Hyperinvasive genotypes of *Neisseria meningitidis* in France. Clin Microbiol Infect 14: 467-472.

4. Brehony C, Jolley KA, Maiden MC (2007) Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiol Rev 31: 15-26.

5. Schneider MC, Exley RM, Ram S, Sim RB, Tang CM (2007) Interactions between *Neisseria meningitidis* and the complement system. Trends Microbiol 15: 233-240.

6. Harrison LH, Trotter CL, Ramsay ME (2009) Global epidemiology of meningococcal disease. Vaccine 27 Suppl 2: B51-63.

7. Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, et al. (2013) Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis.

8. Marshall HS, Richmond PC, Nissen MD, Wouters A, Baber J, et al. (2013) A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine 31: 1569-1575.

9. Hong E, Giuliani MM, Deghmane AE, Comanducci M, Brunelli B, et al. (2013) Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control *Neisseria meningitidis* capsular group X outbreaks in Africa? Vaccine 31: 1113-1116.

10. Caron F, du Chatelet IP, Leroy JP, Ruckly C, Blanchard M, et al. (2011) From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis 11: 455-463.

11. Delbos V, Lemee L, Benichou J, Berthelot G, Taha MK, et al. (2013) Meningococcal carriage during a clonal meningococcal B outbreak in France. Eur J Clin Microbiol Infect Dis.

12. Kellogg DS Jr, Peacock WL Jr, Deacon WE, Brown L, Pirkle DI (1963) *Neisseria gonorrhoeae*. I. Virulence Genetically Linked to Clonal Variation. J Bacteriol 85: 1274-1279.

13. Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, et al. (1998) Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 95: 3140-3145.

displayed as well as the levels of expression of fHbp (Z score) and the bactericidal activity of anti-fHbp antibodies ND = non detectable, NA = non assigned. (DOC)

## Author Contributions

Conceived and designed the experiments: M-KT FC LL. Performed the experiments: LL EH AT A-ED GB M-KT. Analyzed the data: M-KT FC LL. Contributed reagents/materials/analysis tools: A-ED VD ME GB. Wrote the paper: M-KT FC LL.

14. Taha MK, Giorgini D, Ducos-Galand M, Alonso JM (2004) Continuing diversification of *Neisseria meningitidis* W135 as a primary cause of meningococcal disease after emergence of the serogroup in 2000. J Clin Microbiol 42: 4158-4163.

15. Vazquez JA, Arreaza L, Block C, Ehrhard I, Gray SJ, et al. (2003) Interlaboratory comparison of agar dilution and Etest methods for determining the MICs of antibiotics used in management of *Neisseria meningitidis* infections. Antimicrob Agents Chemother 47: 3430-3434.

16. Hong E, Giorgini D, Deghmane AE, Taha MK (2012) Functional impacts of the diversity of the meningococcal factor H binding protein. Vaccine 31: 183-189.

17. Jolley KA, Chan MS, Maiden MC (2004) mstdbNet - distributed multi-locus sequence typing (MLST) databases. BMC Bioinformatics 5: 86.

18. Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, et al. (2009) Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup B *Neisseria meningitidis*. J Infect Dis 200: 379-389.

19. Seib KL, Brunelli B, Brogioni B, Palumbo E, Bambini S, et al. (2011) Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies. Infect Immun 79: 970-981.

20. Maiden MC, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, et al. (2008) Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 197: 737-743.

21. Claus H, Maiden MC, Wilson DJ, McCarthy ND, Jolley KA, et al. (2005) Genetic analysis of meningococci carried by children and young adults. J Infect Dis 191: 1263-1271.

22. Marsh JW, Shutt KA, Pajon R, Tulenko MM, Liu S, et al. (2011) Diversity of factor H-binding protein in *Neisseria meningitidis* carriage isolates. Vaccine 29: 6049-6058.

23. Taha MK (2013) Immunisation against meningococcus B. Lancet 382: 936.

24. Loh E, Kugelberg E, Tracy A, Zhang Q, Gollan B, et al. (2013) Temperature triggers immune evasion by *Neisseria meningitidis*. Nature 502: 237-240.

25. Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, et al. (2013) Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 13: 416-425.

26. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E (2003) Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. Bmj 326: 365-366.